Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11950-11954

  Song, Fei ^a   Fux, Robert ^a   Provacia, Lisette B ^b   Volz, Asisa ^a   Eickmann, Markus ^c   Becker, Stephan ^c,d   Osterhaus, Albert D M E ^b   Haagmans, Bart L ^b   Suttera, Gerd ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d German Centre for Infection Research (DZIF)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORONAVIRUS SPIKE PROTEIN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; DISEASE SEVERITY; GENETIC STABILITY; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; VACCINIA VIRUS; VIROGENESIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS; DRUG CARRIERS; GENETIC VECTORS; GENOMIC INSTABILITY; MICE; MICE, INBRED BALB C; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84886937421     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01672-13     Document Type: Article

References (30)

1. Bermingham A, Brown MA, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Fouchier RA, Zambon M. 2012. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to United Kingdom from the Middle East. Euro Surveill. 17:pii=20290. http://www.eurosurveillance.org/viewarticle.aspx?articleid=20290.
2. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3(6):e00473-12. doi:10.1128/mBio.00473-12.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RAM. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820.
4. Chan JFW, Chan KH, Choi GKY, To KKW, Tse H, Cai JP, Yeung ML, Cheng VC, Chen H, Che XY, Lau SK, Woo PC, Yuen KY. 2013. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207:1743-1752.
5. Chan RWY, Poon LLM. The emergence of human coronavirus EMC: how scared should we be? mBio 4(2):e00191-13. doi:10.1128/mBio.00191-13.
6. Raj VS, Mou H, Smits SL, Dekkers DHW, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus- EMC. Nature 495:251-254.
7. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. 2009. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7:226-236.
8. Enjuanes L, DeDiego ML, Alvarez E, Deming D, Sheahan T, Baric R. 2008 Vaccines to prevent severe acute respiratory syndrome coronavirusinduced disease. Virus Res. 133:45-62.
9. Mayr A, Munz E. 1964. Veränderung von Vaccinevirus durch Dauerpassagen in Hühnerembryofibroblastenkulturen. Zentralbl. Bakteriol. B. 195: 24-35.
10. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virusMVAand their influence on virulence. J. Gen. Virol. 72:1031-1038.
11. Sutter G, Moss B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851.
12. Gilbert SC. 2013. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31:4241-4246.
13. Kremer M, Volz A, Kreijtz JCM, Fux R, Lehmann M, Sutter G. 2012. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol. Biol. 890:59-92.
14. Volz A, Sutter G. 2013. Protective efficacy of modified vaccinia virus Ankara in preclinical studies. Vaccine 31:4235-4240.
15. Wyatt LS, Shors ST, Murphy BR, Moss B. 1996. Development of a replication- deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458.
16. Bertholet C, Drillien R, Wittek R. 1985. One hundred base pairs of 5= flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc. Natl. Acad. Sci. U. S. A. 82:2096-2100.
17. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. 2013 The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87:9379-9383.
18. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101:6641-6646.
19. Schwegmann-Wessels C, Al-Falah M, Escors D, Wang Z, Zimmer G, Deng H, Enjuanes L, Naim HY, Herrler G. 2004. A novel sorting signal for intracellular localization is present in the S protein of a porcine coronavirus but absent from severe acute respiratory syndrome-associated coronavirus. J. Biol. Chem. 279:43661-43666.
20. Shen S, Tan TP, Tan YJ. 2007. Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol. Biol. 379: 127-135.
21. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von Hahn T, Simmons G, Hofmann H, Pöhlmann S. 2013. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 87:5502-5511.
22. Chan CM WP, Lau SK, Tse H, Chen HL, Li F, Zheng BJ, Chen L, Huang JD, Yuen KY. 2008. Spike protein, S, of human coronavirus HKU1: role in viral life cycle and application in antibody detection. Exp. Biol. Med. 233: 1527-1536.
23. de Haan CAM, Stadler K, Godeke G-J, Bosch BJ, Rottier PJM. 2004. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J. Virol. 78:6048-6054.
24. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011-1033.
25. Heald-Sargent T, Gallagher T. 2012. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 4:557-580.
26. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. 2005. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79:2678-2688.
27. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10:871-875.
28. Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K. 2008. Animal models and vaccines for SARS-CoV infection. Virus Res. 133:20-32.
29. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JS. 2011. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J. Virol. 85:10582-10597.
30. Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJ. 1990. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64:1407-1409.